Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche's Divarasib Cuts Death Risk By 44% In Phase 3 KRAS G12C-Mutated Lung Cancer Study

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Roche's Divarasib has demonstrated a 44% reduction in death risk in a Phase 3 trial for KRAS G12C-mutated lung cancer patients, signifying a major advancement in targeted cancer therapy.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 2 sources have reported it between 25 Oct 2026 and 26 Oct 2026.

◆ ◆ The Wire takeaway

You must incorporate KRAS G12C mutation screening into your trial designs or drug development plans immediately as Divarasib's success resets expectations for lung cancer treatments.

◆ Coverage

2 sources · first reported 25 Oct 2026 · latest 26 Oct 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryclinical-triallung-cancertargeted-therapypharma-innovation